Hairong Pharma is a technology-based enterprise focusing on the rapid development of the biopharmaceutical field, a strategic emerging industry. In the short term, the company will adhere to the R&D and industrialization of innovative drugs and the first domestic generic drugs, and adopt a win-win model such as partial equity transfer, sales commission, and market distribution to gain profits and maintain operations; Realize the industrialization of its own products, and eventually develop into a comprehensive pharmaceutical enterprise integrating R&D, production and sales. Recently, Hairong Pharma has released a fixed increase plan to Gui Shaofeng and Xi’an Ruilian New Materials Co., Ltd. No more than 1,179,900 shares are to be issued, the amount of financing is no more than RMB 56 million, and the issue price of the shares is RMB 47.46.
This article is reproduced from: https://www.itjuzi.com/investevent/13647791
This site is for inclusion only, and the copyright belongs to the original author.